(Q56832288)

3

0 references

Matthias Schwab

4

object named as

Matthias Schwab

0 references

author name string

Dagmar Busse

1

0 references

Silke Templin

2

0 references

Michel Eichelbaum

6

0 references

Kari T. Kivistö

European Journal of Clinical Pharmacology

7

0 references

publication date

4 July 2006

0 references

published in

0 references

volume

62

0 references

issue

8

0 references

page(s)

613-619

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s00228-006-0154-7

0 references

cites work

Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography

1 reference

https://api.crossref.org/works/10.1007%2FS00228-006-0154-7

Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-006-0154-7

Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-006-0154-7

The mechanism of action of the optical enantiomers of verapamil against ischaemia-induced arrhythmias in the conscious rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-006-0154-7

R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-006-0154-7

Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina.

21 January 2018

1 reference

12 December 2020

Optical isomers of verapamil on canine heart. Prevention of ventricular fibrillation induced by coronary artery occlusion, impaired atrioventricular conductance and negative inotropic and chronotropic effects

1 reference

12 December 2020

Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism

1 reference

12 December 2020

Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil

1 reference

12 December 2020

Prolongation of verapamil elimination kinetics during chronic oral administration

1 reference

12 December 2020

Relationship of antiarrhythmic to inotropic activity and antiarrhythmic qualities of the optical isomers of verapamil

1 reference

12 December 2020

The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans

1 reference

12 December 2020

Chronopharmacology of intravenous and oral modified release verapamil.

1 reference

12 December 2020

Effects on atrioventricular conduction and blood flow of enantiomers of verapamil and of tetrodotoxin injected into the posterior and the anterior septal artery of the atrioventricular node preparation of the dog

1 reference

12 December 2020

Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis

1 reference

12 December 2020

Management of atrial fibrillation: therapeutic options and clinical decisions

1 reference

12 December 2020

Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing

1 reference

12 December 2020

Verapamil disposition kinetics in chronic atrial fibrillation

1 reference

12 December 2020

Clinical pharmacokinetics of verapamil in patients with atrial fibrillation

1 reference

12 December 2020

Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil

1 reference

12 December 2020

Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction

1 reference

12 December 2020

Concise review of atrial fibrillation: treatment update considerations in light of AFFIRM and RACE.

1 reference

12 December 2020

Electrophysiologic effects of dextro- and levo-verapamil on sinus node and AV node function in humans

1 reference

12 December 2020

Guidelines for the clinical management of atrial fibrillation: a practical perspective

1 reference

12 December 2020

Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil.

1 reference

12 December 2020

Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy

1 reference

12 December 2020

Calcium antagonists in hypertension: from hemodynamics to outcomes

1 reference

12 December 2020

Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension

1 reference

12 December 2020

1 reference

12 December 2020

Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer

1 reference

12 December 2020

Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil

1 reference

12 December 2020

Digitalis and verapamil in atrial fibrillation and flutter. Is verapamil now the preferred agent?

1 reference

12 December 2020

Differential effect of verapamil isomers on sinus node and AV junctional region

1 reference

12 December 2020

Acute treatment of atrial fibrillation

1 reference

12 December 2020

Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. 1984

1 reference

12 December 2020

The burden of atrial fibrillation: should we abandon antiarrhythmic drug therapy?

1 reference

12 December 2020